Associated Feature — Peritumoral Edema
New in BI-RADS v2025. Peritumoral edema is defined as T2-hyperintense signal in the tissue immediately surrounding a lesion, representing fluid accumulation in the peritumoral stroma. It was not included as a formal lexicon descriptor in the BI-RADS 5th edition and is recognized in v2025 as an associated feature that may modify suspicion.
Edition Conflict
The BI-RADS 5th edition did not include peritumoral edema as a standardized associated feature. Radiologists may have described it informally, but it had no formal lexicon entry. BI-RADS v2025 adds it as a codified descriptor under Associated Features. Use the v2025 terminology for current practice.
Definition
- T2-hyperintense signal in the peritumoral tissue, extending beyond the margins of the enhancing lesion
- Represents interstitial fluid accumulation in breast parenchyma and stroma surrounding the finding
- Must be distinguished from diffuse background parenchymal enhancement or normal fibroglandular tissue signal
- Best assessed on dedicated fat-suppressed T2-weighted or STIR sequences where fluid is bright and fat is suppressed
Imaging Appearance
T2-Weighted / STIR
- High signal intensity surrounding the lesion, typically irregular or flame-shaped
- May extend along ductal or fascial planes
- Can be subtle — compare signal to normal contralateral breast parenchyma or uninvolved ipsilateral tissue
T1-Weighted (Pre-contrast)
- Low to intermediate signal; often not conspicuous
- Not reliably detected on T1 alone
Post-contrast (T1 Fat-Sat)
- Edema itself does not enhance (unlike tumor or inflammation)
- The enhancing lesion is surrounded by a non-enhancing halo of T2-bright signal
- Helps differentiate edema from non-mass enhancement, which does enhance
DWI
- Edema shows high signal on DWI due to T2 shine-through but typically has high ADC values (not truly restricted diffusion)
- The central malignant lesion shows truly restricted diffusion (low ADC)
Clinical Significance
- Associated with biologically aggressive malignancies: higher tumor grade, triple-negative and HER2-positive subtypes
- Correlates with lymphovascular invasion (LVI) and increased risk of axillary lymph node metastases
- May indicate a larger area of microscopic tumor infiltration beyond the visible enhancing margin
- In the setting of a suspicious mass, peritumoral edema increases the positive predictive value for malignancy
- Extensive peritumoral edema may impact surgical planning — wider excision margins or consideration of mastectomy
- Can also occur with benign etiologies: post-biopsy change, abscess, fat necrosis, diabetic mastopathy
Board Pearl
Peritumoral edema is a new v2025 associated feature. Its presence around a suspicious mass increases concern for malignancy and correlates with lymph node metastases and lymphovascular invasion. However, always check for recent biopsy or infection, which can produce the same appearance.
Differential Diagnosis
| Cause | Key Distinguishing Features |
|---|---|
| Invasive carcinoma | Irregular/spiculated enhancing mass + restricted diffusion + edema; clinical history of palpable lump |
| Post-biopsy change | History of recent biopsy; biopsy clip present; edema centered on biopsy tract; resolves over weeks |
| Breast abscess | Rim-enhancing collection; clinical signs of infection (erythema, pain, fever); surrounding edema may be extensive |
| Fat necrosis | History of trauma or surgery; may contain fat signal on T1; variable enhancement pattern |
| Inflammatory breast cancer | Diffuse skin thickening + edema involving entire breast; skin enhancement; non-mass enhancement pattern |
| Diabetic mastopathy | Bilateral; low signal on all sequences; minimal enhancement; clinical context of type 1 diabetes |
Board Pearl
When peritumoral edema is seen without a discrete enhancing mass, consider inflammatory breast cancer — which may present with diffuse edema, skin thickening, and non-mass enhancement rather than a focal mass.
Pitfalls
- Confusing edema with NME: Peritumoral edema does not enhance on post-contrast sequences. If the T2-bright area enhances, it is likely non-mass enhancement or tumor extension, not edema alone.
- Ignoring benign causes: Post-procedural edema after biopsy can persist for 4–6 weeks. Always correlate with biopsy history and clip location before attributing edema to malignancy.
- Overcalling on non-fat-suppressed T2: Without fat suppression, normal fat signal can obscure or mimic edema. Always use fat-suppressed T2 or STIR for accurate assessment.
- Underestimating extent of disease: Peritumoral edema may mask the true tumor margin. MRI may underestimate the extent of enhancing disease when surrounded by extensive edema.
- Missing on abbreviated protocols: If the MRI protocol does not include a dedicated T2 sequence, peritumoral edema will not be detected — it is invisible on contrast-enhanced T1 sequences alone.
Board Pearl
Peritumoral edema is assessed on T2-weighted sequences, not on post-contrast T1. A protocol without T2/STIR will miss this finding entirely. This is one reason the v2025 lexicon emphasizes including T2 in the standard breast MRI protocol.
Reporting
When present, report as: “Associated feature: peritumoral edema” and note the extent (focal vs. extensive). The v2025 lexicon does not assign a specific BI-RADS upgrade based on edema alone, but it should be documented as it contributes to the overall assessment and may influence management.